This study is for people aged 18 years and older who have stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer. This is a type of cancer that starts in the lungs and has been removed by surgery. The research is looking at how well an investigational medication called pembrolizumab works when added to regular chemotherapy. Chemotherapy uses special drugs to stop cancer cells from growing. Pembrolizumab is a type of immunotherapy, which means it helps your immune system fight the cancer.
**Key Points to Consider:**
- **Study Length:** Participation could last several months, depending on your treatment plan.
- **Number of Visits:** Multiple clinic visits will be required for treatment and check-ups.
- **Age Criteria:** Must be 18 years or older to join the study.
If you meet the age and cancer stage criteria and are interested in learning more, you can discuss this study with your doctor to see if it's right for you. It's important to consider the time commitment and whether the study fits your personal health needs.